1. Home
  2. ESCA vs CHRS Comparison

ESCA vs CHRS Comparison

Compare ESCA & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Escalade Incorporated

ESCA

Escalade Incorporated

N/A

Current Price

$18.63

Market Cap

257.2M

ML Signal

N/A

Logo Coherus BioSciences Inc.

CHRS

Coherus BioSciences Inc.

N/A

Current Price

$1.40

Market Cap

296.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ESCA
CHRS
Founded
1922
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Recreational Games/Products/Toys
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
257.2M
296.8M
IPO Year
1995
2014

Fundamental Metrics

Financial Performance
Metric
ESCA
CHRS
Price
$18.63
$1.40
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$5.51
AVG Volume (30 Days)
23.1K
930.3K
Earning Date
04-30-2026
05-07-2026
Dividend Yield
3.50%
N/A
EPS Growth
6.45
472.00
EPS
0.32
N/A
Revenue
$180,541,000.00
N/A
Revenue This Year
$4.15
$73.08
Revenue Next Year
N/A
$30.94
P/E Ratio
$58.22
N/A
Revenue Growth
2.71
N/A
52 Week Low
$11.41
$0.72
52 Week High
$21.32
$2.62

Technical Indicators

Market Signals
Indicator
ESCA
CHRS
Relative Strength Index (RSI) 49.40 37.75
Support Level $17.33 $1.37
Resistance Level $18.72 $1.42
Average True Range (ATR) 0.57 0.08
MACD -0.00 -0.01
Stochastic Oscillator 43.19 14.81

Price Performance

Historical Comparison
ESCA
CHRS

About ESCA Escalade Incorporated

Escalade Inc manufactures and distributes sporting goods for a varied range of activities. These sports include archery, table tennis, basketball goals, trampoline, play systems, fitness, game tables like hockey and soccer, billiards, darting, and other outdoor games. These products are sold under the brand names like Goalrilla, Goalsetter, Woodplay, Silverback, Nodor, Rage, Child Life, among others. The geographic segments in which the company operates are the United States, Canada, Australia, and Other regions.

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.

Share on Social Networks: